Literature DB >> 35301424

Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.

Antonio Inserra1, Justine P Enns1, Danilo De Gregorio1,2, Athanasios Markopoulos1, Michael Pileggi1, Youssef El Rahimy1, Martha Lopez-Canul1, Stefano Comai1,3,2, Gabriella Gobbi4.   

Abstract

Lysergic acid diethylamide (LSD) is a serotonergic psychedelic compound receiving increasing interest due to putative anxiolytic and antidepressant properties. However, the potential neurobiological mechanisms mediating these effects remain elusive. Employing in vivo electrophysiology, microionthophoresis, behavioral paradigms and morphology assays, we assessed the impact of acute and chronic LSD administration on anxiety-like behavior, on the cortical dendritic spines and on the activity of serotonin (5-HT) neurons originating in the dorsal raphe nucleus (DRN) in male mice exposed to chronic restraint stress. We found that while the acute intraperitoneal (i.p.) administration of LSD (5, 15 and 30 and 60 μg/kg) did not produce any anxiolytic or antidepressant effects in non-stressed mice, the dose of 30 µg/kg (daily for 7 days) prevented the stress-induced anxiety-like behavior and the stress-induced decrease of cortical spine densitiy. Interestingly, while LSD acutely decreased the firing activity of 5-HT neurons, repeated LSD increased their basal firing rate and restored the low 5-HT firing induced by stress. This effect was accompanied by a decreased inhibitory response of 5-HT neurons to microiontophoretic applications of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-N,N-dipropyl-2-aminotetralin). In conclusion, repeated LSD prevents the exacerbation of anxiety-like behavior following chronic stress exposure, but has no behavioral effects in non-stressed mice. These effects are paralleled by increased cortical spinogenesis and an enhancement of 5-HT neurotransmission which might be due to 5-HT1A receptors desensitization. Increased cortical spine density and enhancement of serotonergic neurotransmission may thus represent a candidate mechanism which mediate the therapeutic effects of serotonergic psychedelics on stress-induced anxiety.
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35301424      PMCID: PMC9018770          DOI: 10.1038/s41386-022-01301-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   8.294


  67 in total

Review 1.  Coping with the forced swim stressor: Current state-of-the-art.

Authors:  Marc L Molendijk; E Ronald de Kloet
Journal:  Behav Brain Res       Date:  2019-02-06       Impact factor: 3.332

2.  Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus.

Authors:  Francis Rodriguez Bambico; Tommaso Cassano; Sergio Dominguez-Lopez; Noam Katz; Claire Dominique Walker; Daniele Piomelli; Gabriella Gobbi
Journal:  Neuropsychopharmacology       Date:  2010-06-23       Impact factor: 7.853

Review 3.  The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior.

Authors:  Kathryn G Commons; Aram B Cholanians; Jessica A Babb; Daniel G Ehlinger
Journal:  ACS Chem Neurosci       Date:  2017-03-22       Impact factor: 4.418

Review 4.  Current advances and trends in the treatment of depression.

Authors:  P Blier; C de Montigny
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

Review 5.  Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis?

Authors:  Francis Rodriguez Bambico; Catherine Belzung
Journal:  Curr Top Behav Neurosci       Date:  2013

Review 6.  Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.

Authors:  Antonio Inserra; Danilo De Gregorio; Gabriella Gobbi
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

7.  Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.

Authors:  Luca Santarelli; Michael Saxe; Cornelius Gross; Alexandre Surget; Fortunato Battaglia; Stephanie Dulawa; Noelia Weisstaub; James Lee; Ronald Duman; Ottavio Arancio; Catherine Belzung; René Hen
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

Review 8.  d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.

Authors:  Danilo De Gregorio; Stefano Comai; Luca Posa; Gabriella Gobbi
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

9.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

10.  Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.

Authors:  Peter Gasser; Dominique Holstein; Yvonne Michel; Rick Doblin; Berra Yazar-Klosinski; Torsten Passie; Rudolf Brenneisen
Journal:  J Nerv Ment Dis       Date:  2014-07       Impact factor: 2.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.